The treatment of patients with the PD1 inhibitor pembrolizumab yields benefit in the second-line metastatic urothelial cancer setting. Two new trials have studied pembrolizumab monotherapy in other patients with urothelial carcinoma: an open-label phase II trial has enrolled patients with high-risk BCG-refractory non-muscle-invasive disease, and a phase III trial has compared three first-line treatment options for patients with metastatic disease. However, these trials have shown conflicting results.
This is a preview of subscription content, log in via an institution to check access.
References
Bellmunt, J. et al. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N. Engl. J. Med. 376, 1015–1026 (2017).
Balar, A. V. et al. First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study. Lancet Oncol. 18, 1483–1492 (2017).
O’Donnell, P. H. et al. First-line pembrolizumab (pembro) in cisplatin-ineligible patients with advanced urothelial cancer (UC): response and survival results up to five years from the KEYNOTE-052 phase 2 study. J. Clin. Oncol. 39 (Suppl. 15), 4508 (2021).
Powles, T. et al. Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial. Lancet Oncol. 22, 931–945 (2021).
Balar, A. V. et al. Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study. Lancet Oncol. 22, 919–930 (2021).
Galsky, M. D. et al. Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial. Lancet 395, 1547–1557 (2020).
FDA. FDA alerts health care professionals and oncology clinical investigators about an efficacy issue identified in clinical trials for some patients taking Keytruda (pembrolizumab) or Tecentriq (atezolizumab) as monotherapy to treat urothelial cancer with low expression of PD-L1. FDA https://www.fda.gov/drugs/drug-safety-and-availability/fda-alerts-health-care-professionals-and-oncology-clinical-investigators-about-efficacy-issue (2018).
FDA. April 27-29, 2021: meeting of the Oncologic Drugs Advisory Committee meeting announcement. FDA https://www.fda.gov/advisory-committees/advisory-committee-calendar/april-27-29-2021-meeting-oncologic-drugs-advisory-committee-meeting-announcement-04272021-04292021#event-materials (2021).
Hanna, N. H. et al. Therapy for stage IV non-small-cell lung cancer with driver alterations: ASCO and OH (CCO) joint guideline update. J. Clin. Oncol. 39, 1040–1091 (2021).
Bajorin, D. F. et al. Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma. N. Engl. J. Med. 384, 2102–2114 (2021).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
J.B.A.-C. serves in the Speakers’ Bureau for Bristol-Myers Squibb and serves on the advisory board of Pfizer, Merck and EMD Serono.
Rights and permissions
About this article
Cite this article
Aragon-Ching, J.B. Pembrolizumab use in bladder cancer: a tale of two trials. Nat Rev Urol 18, 577–578 (2021). https://doi.org/10.1038/s41585-021-00499-5
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41585-021-00499-5
- Springer Nature Limited
This article is cited by
-
Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons
Cell Communication and Signaling (2022)
-
Combination therapy with immune checkpoint inhibitors (ICIs); a new frontier
Cancer Cell International (2022)